Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · IEX Real-Time Price · USD
30.00
-0.60 (-1.96%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Dianthus Therapeutics Market Cap
Dianthus Therapeutics has a market cap or net worth of $524.21 million as of March 28, 2024. Its market cap has increased by 1,054.65% in one year.
Market Cap
524.21M
Enterprise Value
351.08M
1-Year Change
1,054.65%
Ranking
Category
Stock Price
$30.00
Market Cap Chart
Since June 21, 2018, Dianthus Therapeutics's market cap has increased from $499.10M to $524.21M, an increase of 5.03%. That is a compound annual growth rate of 0.85%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 28, 2024 | 880.40M | -1.96% |
Mar 27, 2024 | 898.00M | -2.92% |
Mar 26, 2024 | 925.00M | 1.70% |
Mar 25, 2024 | 909.50M | -2.97% |
Mar 22, 2024 | 937.30M | 14.32% |
Mar 21, 2024 | 819.90M | 104.16% |
Mar 20, 2024 | 401.60M | 2.50% |
Mar 19, 2024 | 391.80M | 0.36% |
Mar 18, 2024 | 390.40M | -6.06% |
Mar 15, 2024 | 415.60M | 4.37% |
Mar 14, 2024 | 398.20M | -8.29% |
Mar 13, 2024 | 434.20M | 16.50% |
Mar 12, 2024 | 372.70M | 0.30% |
Mar 11, 2024 | 371.60M | -0.21% |
Mar 8, 2024 | 372.40M | -0.75% |
Mar 7, 2024 | 375.20M | 1.32% |
Mar 6, 2024 | 370.30M | 0.84% |
Mar 5, 2024 | 367.20M | -2.68% |
Mar 4, 2024 | 377.30M | -1.13% |
Mar 1, 2024 | 381.60M | 4.06% |
Feb 29, 2024 | 366.70M | 2.69% |
Feb 28, 2024 | 357.10M | -5.50% |
Feb 27, 2024 | 377.90M | 0.08% |
Feb 26, 2024 | 377.60M | 4.28% |
Feb 23, 2024 | 362.10M | 1.83% |
View and export this data all the way back to 2018.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
COMPASS Pathways | 534.37M |
Biomea Fusion | 533.80M |
Phibro Animal Health | 528.98M |
Nevro | 528.41M |
Cibus | 525.35M |
P3 Health Partners | 521.75M |
Revance Therapeutics | 514.83M |
UroGen Pharma | 511.83M |